Brainstorm Cell Therapeutics Stock Investor Sentiment

BCLI Stock  USD 1.74  0.12  7.41%   
Under 55% of Brainstorm Cell's traders are presently thinking to get in. The analysis of the overall investor sentiment regarding Brainstorm Cell Therapeutics suggests that some traders are interested. Brainstorm Cell's investing sentiment shows overall attitude of investors towards Brainstorm Cell Therapeutics.
  

Brainstorm Cell Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Brainstorm Cell can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over six months ago at www.macroaxis.com         
Acquisition by Chaim Lebovits of 15000 shares of Brainstorm Cell at 0.5183 subject to Rule 16b-3
Macroaxis News
over six months ago at news.google.com         
StockNews.com Initiates Coverage on Brainstorm Cell Therapeutics - Defense World
Google News at Macroaxis
over six months ago at www.macroaxis.com         
Acquisition by Chaim Lebovits of 25000 shares of Brainstorm Cell at 0.64 subject to Rule 16b-3
Macroaxis News
over six months ago at www.macroaxis.com         
Acquisition by Chaim Lebovits of 25000 shares of Brainstorm Cell at 0.579 subject to Rule 16b-3
Macroaxis News
over six months ago at finance.yahoo.com         
BrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit From ...
Yahoo News
over six months ago at news.google.com         
Brainstorm Cell Therapeutics Inc. Short Interest Up 5.5 percent in April - Defense World
Google News at Macroaxis
over six months ago at investorplace.com         
BCLI Stock Earnings Brainstorm Cell Reported Results for Q1 2024
sbwire news
over six months ago at finance.yahoo.com         
BrainStorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate U...
Yahoo News
over six months ago at www.macroaxis.com         
Acquisition by Chaim Lebovits of 10000 shares of Brainstorm Cell at 0.49 subject to Rule 16b-3
Macroaxis News
over six months ago at news.google.com         
Do Institutions Own Brainstorm Cell Therapeutics Inc Shares - Yahoo New Zealand News
Google News at Macroaxis
over six months ago at www.macroaxis.com         
Acquisition by Chaim Lebovits of 10000 shares of Brainstorm Cell at 0.4665 subject to Rule 16b-3
Macroaxis News
over six months ago at www.macroaxis.com         
Acquisition by Chaim Lebovits of 20000 shares of Brainstorm Cell at 0.465 subject to Rule 16b-3
Macroaxis News
over six months ago at www.macroaxis.com         
Acquisition by Chaim Lebovits of 66300 shares of Brainstorm Cell at 0.3743 subject to Rule 16b-3
Macroaxis News
over six months ago at www.macroaxis.com         
Acquisition by Chaim Lebovits of 135000 shares of Brainstorm Cell at 0.3753 subject to Rule 16b-3
Macroaxis News
over six months ago at news.google.com         
Windtree Therapeutics and Brainstorm Cell Therapeutics Critical Contrast - Defense World
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Brainstorm Cell that are available to investors today. That information is available publicly through Brainstorm media outlets and privately through word of mouth or via Brainstorm internal channels. However, regardless of the origin, that massive amount of Brainstorm data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Brainstorm Cell news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Brainstorm Cell relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Brainstorm Cell's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Brainstorm Cell alpha.

Brainstorm Cell Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Acquisition by Uri Yablonka of 13333 shares of Brainstorm Cell at 0.75 subject to Rule 16b-3
09/16/2024
2
Brainstorm Cell Therapeutics Research Coverage Started at StockNews.com
09/27/2024
3
Acquisition by Chaim Lebovits of 22000 shares of Brainstorm Cell at 0.228 subject to Rule 16b-3
09/30/2024
4
Acquisition by Chaim Lebovits of 1836 shares of Brainstorm Cell at 3.4272 subject to Rule 16b-3
10/01/2024
5
Brainstorm cell therapeutics CEO acquires 11,308 in stock
10/02/2024
6
Disposition of 9600 shares by Patlis Alla of Brainstorm Cell at 9.51 subject to Rule 16b-3
10/10/2024
7
Acquisition by Chaim Lebovits of 135000 shares of Brainstorm Cell at 0.3753 subject to Rule 16b-3
10/11/2024
8
BrainStorm Cell Therapeutics Presented Positive Survival Data from NurOwn Expanded Access Program at 2024 Annual NEALS Meeting
10/28/2024
9
Acquisition by Arbel Irit of 25333 shares of Brainstorm Cell at 0.75 subject to Rule 16b-3
11/12/2024

Complementary Tools for Brainstorm Stock analysis

When running Brainstorm Cell's price analysis, check to measure Brainstorm Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brainstorm Cell is operating at the current time. Most of Brainstorm Cell's value examination focuses on studying past and present price action to predict the probability of Brainstorm Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Brainstorm Cell's price. Additionally, you may evaluate how the addition of Brainstorm Cell to your portfolios can decrease your overall portfolio volatility.
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Commodity Directory
Find actively traded commodities issued by global exchanges
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Equity Valuation
Check real value of public entities based on technical and fundamental data
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins